Fig 2.

Adjusted least squares mean treatment difference in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 and myeloma-specific module scores. Scores have been adjusted for baseline score, baseline score by visit interaction, and the random assignment stratification factors (baseline β₂-microglobulin levels, prior bortezomib, and prior lenalidomide). For functioning scales, a positive difference is in favor of carfilzomib, lenalidomide, and dexamethasone (KRd). For symptom scales, a negative difference is in favor of KRd. Horizontal bars indicate 95% CIs. (*) Number of patients with data at that time point. (†) Presented in Stewart et al.³ GHS/QoL, Global Health Status/Quality of Life domain; KRd, carfilzomib, lenalidomide, and dexamethasone; Rd, lenalidomide and dexamethasone.